Pulling SEC filings + quote and writing the call…
RARE
Ultragenyx Pharmaceutical Inc.
Next earnings Aug 3, 2026 · consensus $-1.25 EPS, $185M rev
Last earnings +0.8% on 2026-05-05
$29.03
▲ +5.79%$29.03▼ -21.77%
over 1Y
L $18.50EODHDH $41.44
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+5.8%
1W+14.4%
1M+25.5%
3M+43.2%
YTD+23.0%
1Y-21.8%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 25 analysts
Buy
Revenue grew 20.2% YoY; but unprofitable (net margin -85.4%).
Ultragenyx Pharmaceutical Inc. shows $673M in FY2025 revenue (+20.2% YoY), a -85.4% net margin, and 718.8% ROE.
Sources: SEC EDGAR (CIK 0001515673, latest 10-Q filed 2026-05-06) · EODHD · as of 6/23/2026, 4:03:08 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.